Low Dose DCB Showed No Statistically Significant Difference in Patency versus Higher Dose DCB

Learn about COMPARE-1, the world's first head-to-head prospective, randomized (1:1) controlled trial comparing the lower dose paclitaxel Ranger™ DCB (2 μg/mm2) to the higher dose paclitaxel IN.PACT™ DCB (3.5 μg/mm2)

Prof. Dierk Scheinert

PI COMPARE-1 Trial
University of Leipzig, Germany

Prof. Andrew Holden

Auckland University, New Zealand

COMPARE-1 Clinical Trial Overview

Protocol pre-specified interim analysis of first 150 patients (COMPARE pilot) after 12-months of follow-up presented at LINC 2018*

*Results from the 150 patients from the pilot phase. Overall trial will enroll up to 414 patients.

 


About Drug-Eluting Technologies
Clinical Program
Resources Center
News & Events

WANT TO KNOW MORE?

Join our Drug-Eluting Technologies Community

Sign Up for Product Updates

Receive the latest news of Drug Eluting Technologies

SIGN UP